A detailed history of Bank Of America Corp transactions in Axogen, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 470,661 shares of AXGN stock, worth $5.96 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
470,661
Previous 468,435 0.48%
Holding current value
$5.96 Million
Previous $3.78 Million 9.87%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$5.67 - $8.06 $12,621 - $17,941
2,226 Added 0.48%
470,661 $3.41 Million
Q1 2024

May 15, 2024

SELL
$6.63 - $10.69 $353,246 - $569,563
-53,280 Reduced 10.21%
468,435 $3.78 Million
Q4 2023

Feb 14, 2024

SELL
$3.61 - $7.76 $4.62 Million - $9.94 Million
-1,280,998 Reduced 71.06%
521,715 $3.56 Million
Q2 2023

Aug 14, 2023

BUY
$8.5 - $10.38 $231,123 - $282,242
27,191 Added 1.53%
1,802,713 $16.5 Million
Q1 2023

May 12, 2023

SELL
$7.53 - $10.95 $311,613 - $453,143
-41,383 Reduced 2.28%
1,775,522 $16.8 Million
Q4 2022

Feb 10, 2023

SELL
$9.44 - $13.09 $239,417 - $331,988
-25,362 Reduced 1.38%
1,816,905 $18.1 Million
Q3 2022

Nov 14, 2022

BUY
$8.14 - $12.25 $769,531 - $1.16 Million
94,537 Added 5.41%
1,842,267 $22 Million
Q2 2022

Aug 12, 2022

BUY
$6.99 - $10.0 $124,547 - $178,180
17,818 Added 1.03%
1,747,730 $14.3 Million
Q1 2022

May 16, 2022

BUY
$7.26 - $10.7 $1.36 Million - $2 Million
187,205 Added 12.13%
1,729,912 $13.7 Million
Q4 2021

Feb 08, 2022

BUY
$8.8 - $16.0 $4.7 Million - $8.55 Million
534,086 Added 52.95%
1,542,707 $14.5 Million
Q3 2021

Nov 15, 2021

SELL
$15.23 - $21.72 $21,230 - $30,277
-1,394 Reduced 0.14%
1,008,621 $15.9 Million
Q2 2021

Sep 13, 2021

BUY
$17.8 - $23.5 $18 Million - $23.7 Million
1,010,015 New
1,010,015 $21.8 Million

Others Institutions Holding AXGN

About Axogen, Inc.


  • Ticker AXGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 42,283,700
  • Market Cap $535M
  • Description
  • AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...
More about AXGN
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.